| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT04038502 |
| P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
| P17 | country | United States of America | Q30 |
| P582 | end time | 2024-08-30 | |
| P921 | main subject | metastatic prostate carcinoma | Q55779807 |
| P2899 | minimum age | 18 | |
| P1132 | number of participants | 40 | |
| P4844 | research intervention | carboplatin | Q415588 |
| P1813 | short name | BRACeD | |
| P580 | start time | 2019-08-19 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | Multicenter Phase II Study of First-line Carboplatin Followed by Docetaxel Versus First-line Docetaxel Followed by Carboplatin for Treatment of Castration Resistant Prostate Cancer |
Search more.